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Abstract
Problem/Condition: In the United States, acute viral hepatitis most frequently is caused by infection with three
viruses: hepatitis A virus (HAV), hepatitis B virus (HBV), and hepatitis C virus (HCV). These unrelated viruses
are transmitted through different routes and have different epidemiologic profiles. Safe and effective vaccines have
been available for hepatitis B since 1981 and for hepatitis A since 1995. No vaccine exists against hepatitis C.
Reporting Period Covered: Cases in 2006, the most recent year for which data are available, are compared with
those from previous years.
Description of System: Cases of acute viral hepatitis are reported voluntarily to CDC by state and territorial
epidemiologists via CDC’s National Notifiable Disease Surveillance System (NNDSS). Reports are received elec-
tronically via CDC’s National Electronic Telecommunications System for Surveillance (NETSS).
Results: During 1995–2006, hepatitis A incidence declined 90% to the lowest rate ever recorded (1.2 cases per
100,000 population). Declines were greatest among children and in those states where routine vaccination of
children was recommended beginning in 1999. An increasing proportion of cases occurred in adults. During
1990–2006, acute hepatitis B incidence declined 81% to the lowest rate ever recorded (1.6 cases per 100,000
population). Declines occurred among all age groups but were greatest among children aged <15 years. Follow-
ing a peak in the late 1980s, incidence of acute hepatitis C declined through the 1990s; however, since 2003,
rates have plateaued, with a slight increas in reported cases in 2006. In 2006, as in previous years, the majority of
these cases occurred among adults, and injection-drug use was the most common risk factor.
Interpretation: The results documented in this report suggest that implementation of the 1999 recommenda-
tions for routine childhood hepatitis A vaccination in the United States has reduced rates of infection and that
universal vaccination of children against hepatitis B has reduced disease incidence substantially among younger
age groups. Higher rates of hepatitis B continue among adults, particularly males aged 25–44 years, reflecting
the need to vaccinate adults at risk for HBV infection. The decline in hepatitis C incidence that occurred in the
1990s was attributable primarily to a decrease in incidence among injection-drug users. The reasons for this
decrease were unknown but likely reflected changes in behavior and practices among injection-drug users.
Public Health Actions: The expansion in 2006 of recommendations for routine hepatitis A vaccination to include
all children in the United States aged 12–23 months is expected to reduce hepatitis A rates further. Ongoing
hepatitis B vaccination programs ultimately will eliminate domestic HBV transmission, and increased vaccina-
tion of adults with risk factors will accelerate progress toward elimination. Prevention of hepatitis C relies on
identifying and counseling uninfected persons at risk for hepatitis C (e.g., injection-drug users) regarding ways to
protect themselves from infection and on identifying and preventing transmission of HCV in health-care settings.
Introduction
Viral hepatitis is caused by infection with any of at least
five distinct viruses, of which the three most commonly
identified in the United States are hepatitis A virus (HAV),
hepatitis B virus (HBV), and hepatitis C virus (HCV). All
three of these unrelated viruses can produce an acute ill-
ness characterized by nausea, malaise, abdominal pain, and
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jaundice. HBV and HCV also can produce a chronic infec-
tion that is associated with an increased risk for chronic
liver disease and hepatocellular carcinoma.
This report describes the burden of acute disease attrib-
uted to infection with HAV, HBV, and HCV and describes
acute disease trends in recent years. These data can be used
to develop and evaluate prevention strategies and identifies
persons in need of postexposure prophylaxis. The data on
acute illness presented in this report do not include the
burden of disease caused by chronic infection with HBV
or HCV, both of which remain a substantial public health
problem.
Hepatitis A Virus
HAV is transmitted through the fecal-oral route, spread-
ing primarily through close personal contact. During 1987–
1997, an average of 28,000 cases of hepatitis A occurred
per year in the United States (range: 23,112–35,821),
making hepatitis A one of the country’s most frequently
reported notifiable diseases. However, effective vaccines to
prevent HAV infection have been available in the United
States since 1995. These vaccines have provided public
health authorities with the opportunity to reduce disease
incidence in the United States substantially and potentially
to eliminate indigenous transmission.
In 1996, CDC’s Advisory Committee on Immunization
Practices (ACIP) recommended administration of hepatitis
A vaccine for persons at increased risk, including interna-
tional travelers, men who have sex with men (MSM),
injection- and noninjection-drug users, and children liv-
ing in communities with high rates of disease (1). In 1999,
ACIP also recommended that routine vaccination be imple-
mented for children living in 11 states with average hepati-
tis A rates during 1987–1997 of >20 cases per 100,000
population and also be considered for children in six states
with rates of 10–20 cases per 100,000 population (2). In
2005, ACIP expanded these recommendations to include
routine vaccination of children in all 50 states (3).
Hepatitis B Virus
HBV is transmitted by percutaneous or mucosal expo-
sure to the blood or body fluids of an infected person, most
often through injection-drug use [IDU], sexual contact with
an infected person, or contact from an infected mother to
her infant during delivery. Transmission of HBV also can
occur in settings involving nonsexual interpersonal contact
for an extended period (e.g., among household contacts of
a person with chronic HBV infection). In 1991, a compre-
hensive strategy was recommended for the elimination of
HBV transmission in the United States (4,5). The four
elements of this strategy are 1) universal vaccination of in-
fants beginning at birth, 2) prevention of perinatal HBV
infection through routine screening of all pregnant women
for HBV infection and the provision of immunoprophylaxis
to infants born to infected women or to women of unknown
infection status, 3) routine vaccination of previously
unvaccinated children and adolescents, and 4) vaccination
of adults at increased risk for infection (including health
care workers, dialysis patients, household contacts and sex
partners of persons with chronic HBV infection, recipients
of certain blood products, persons with a recent history of
multiple sex partners or an STD, MSM, and injection-drug
users).
Hepatitis C Virus
HCV also is transmitted percutaneously. With an esti-
mated 3.2 million chronically infected persons nationwide,
HCV infection is the most common bloodborne infection
in the United States (6). No vaccine against HCV infec-
tion exists. National recommendations for prevention and
control of HCV infection (7), issued in 1998, emphasize
primary prevention activities to reduce the risk for HCV
transmission. These activities include screening and test-
ing of blood donors, viral inactivation of plasma-derived
products, risk-reduction counseling and screening of per-
sons at risk for HCV infection, and routine practice of
infection control in health-care settings.
Methods
Conditions for Which Surveillance is
Conducted
National surveillance is conducted for acute hepatitis A,
B, and C. The case definitions for these conditions are
approved by the Council of State and Territorial Epidemi-
ologists (CSTE) and are provided in this report.
Data Sources
Cases of acute viral hepatitis are reported to CDC weekly
by state and territorial health departments to CDC’s
National Notifiable Diseases Surveillance System (NNDSS).
Since January 1, 2002, all reports have been submitted
electronically to CDC via the National Electronic Telecom-
munications System for Surveillance (NETSS).
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States’ participation in reporting nationally notifiable
diseases, including acute viral hepatitis, to CDC is volun-
tary. All states collect and report basic information (e.g.,
event date, source of report, and demographic characteristics)
regarding cases of acute viral hepatitis that are identified in
their states. States also are asked to report additional infor-
mation (e.g., laboratory test results, clinical information,
and exposure history) regarding investigated cases, but com-
pleteness of reporting of these additional data varies.
As in previous years, approximately 40% of case reports
received by CDC include any of these additional data. In-
formation regarding state-specific reporting profiles is pro-
vided in this report (Table 1).
Case Definitions for Acute Viral
Hepatitis
In 2006, cases were required to meet the clinical defini-
tion for acute hepatitis and virus-specific laboratory crite-
ria for diagnosis specified in the following CSTE-approved
case definitions.
Clinical Case Definition
Acute hepatitis was defined as acute illness with 1) dis-
crete onset of symptoms (e.g., nausea, anorexia, fever,
malaise, or abdominal pain) and 2) jaundice or elevated
serum aminotransferase levels.
Laboratory Criteria for Diagnosis of
Hepatitis
Because the clinical characteristics are the same for all
types of acute viral hepatitis, laboratory testing is needed
to identify the specific viral cause of illness. The laboratory
criteria for confirming each type of acute viral hepatitis are
as follows:
• Acute hepatitis A
— Immunoglobulin M (IgM) antibody to hepatitis A
virus (anti-HAV) positive
• Acute hepatitis B
— IgM antibody to hepatitis B core antigen (anti-HBc)
positive or hepatitis B surface antigen (HBsAg)
positive and
— IgM anti-HAV negative (if performed)
• Acute hepatitis C
— Serum alanine aminotransferase levels higher than
seven times the upper limit of normal, and
— IgM anti-HAV negative, and
— IgM anti-HBc negative, or if not performed, HBsAg
negative, and
— One of the following
º Antibody to hepatitis C virus (anti-HCV) screen-
ing-test-positive, verified by an additional more
specific assay (e.g., RIBA for anti-HCV or nucleic
acid testing for HCV RNA)
OR
º Anti-HCV screening-test positive with a signal
to cut-off ratio predictive of a true positive as
determined for the particular assay (e.g., >3.8
for the enzyme immunoassays).
Case Classification
For this analysis, a confirmed case was one that met the
clinical case definition and was laboratory-confirmed. For
hepatitis A, a case also was considered confirmed that met
the clinical case definition and was diagnosed in a person
who had an epidemiologic link to a person who had
laboratory-confirmed hepatitis A (i.e., household or sexual
contact with an infected person during the 15–50 days
before the onset of symptoms).
Analyses
Incidence Calculations
For this analysis, crude rates per 100,000 population were
calculated using Bureau of the Census estimates of the U.S.
resident population in 2006. The following U.S. geographic
regions were used: Midwest, Northeast, South, and West.*
Frequency Analysis
For this analysis, the percentage of persons who reported
a specific risk factor was determined by using the number
of persons who reported any information, positive or nega-
tive, regarding that exposure as the denominator. Depend-
ing on the type of hepatitis, the percentage of case reports
that included any risk factor information ranged from 30%–
40%. Multiple risk factors may be reported for a single
person. Consequently, the percentages of persons with
specific risk factors might total >100%.
* Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri,
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin;
Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New
Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South:
Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia,
Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma,
South Carolina, Tennessee, Texas, Virginia, and West Virginia; and West:
Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada,
New Mexico, Oregon, Utah, Washington, and Wyoming.
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Results
Acute Viral Hepatitis A
Overall Incidence
Historically, acute hepatitis A rates have varied cyclically,
with nationwide increases every 10–15 years. The national
rate of hepatitis A has declined steadily since the last peak
in 1995. In 2006, a total of 3,579 acute symptomatic cases
of hepatitis A were reported, the national incidence (1.2 per
100,000 population) was the lowest ever recorded (Figure 1;
Tables 2 and 3). After asymptomatic infection and
underreporting were taken into account, an estimated
32,000 new infections occurred in 2006 (8).
Rates by Region
In addition to temporal variation, historically, hepatitis
A rates have varied geographically, with higher rates reported
in the western region of the United States. However, inci-
dence in the West has declined substantially, most notably
after issuance in 1999 of recommendations for routine child-
hood vaccination in states with consistently elevated rates
of hepatitis A (2). In 2006, rates in the West were approxi-
mately equal to those in other regions of the United States
(Figures 2 and 3).
Rates by Age
Incidence of hepatitis A varies by age. Since the last na-
tionwide increase in 1995, rates have declined among all
age groups, but the greatest decreases have occurred among
children. Historically, the highest rates were observed
among children and young adults; the lowest rates were
among persons aged >40 years. However, since 1997, rates
among children have declined more rapidly than rates
among adults, and, in 2006, rates were similar across all
age groups, ranging from 0.7 cases per 100,000 popula-
tion among children aged <5 years to 1.4 cases per 100,000
population among persons aged 5–14 years (Figure 4). Since
2000, the lowest rates have occurred among children aged
<5 years. However, asymptomatic infection is common
among young children, and symptomatic cases in children
aged <5 years represent only a limited proportion of infec-
tions that occur in this age group.
Rates by Sex
Rates of hepatitis A consistently have been higher among
males than among females, and, during the late 1990s
through 2001, the difference in the sex-specific rates
increased until nearly two male cases were observed for
every female case. However, beginning in 2001, rates
declined more among males than among females, and, since
2003, the ratio of the number of male cases to female cases
has ranged from 1.2 to 1.3. In 2006, overall incidence
among males was 1.3 cases per 100,000 population com-
pared with 1.1 cases per 100,000 population among fe-
males. The difference in hepatitis A rates by sex was highest
among persons aged 30–49 years (Figures 5 and 6).
Rates by Race and Ethnicity
Hepatitis A rates have differed historically by race; the
highest rates occurred among American Indian/Alaska
Natives (AI/ANs), and the lowest rates have occurred among
Asians/Pacific Islanders (APIs). However, rates among
AI/ANs, which were >60 cases per 100,000 population
before 1995, have decreased dramatically, and, since 2003,
have been lower than those for other races. In 2006, the
rate for AI/ANs was 0.5 cases per 100,000 population. Hepa-
titis A rates also have differed by ethnicity; rates among
Hispanics have consistently been higher compared with
non-Hispanics. Rates among Hispanics have decreased since
1997 but remain higher than those for non-Hispanics
(Figure 7).
Reported Risk Factors
In 2006, among cases for which information regarding
exposures during the incubation period was collected, the
most frequently identified risk factor for hepatitis A was
international travel (reported by 15% of case patients over-
all). As in previous years, the majority of travel-related cases
were associated with travel to Mexico and Central/South
America (72%). As HAV transmission in the United States
has decreased, cases among travelers to countries in which
hepatitis is endemic have accounted for an increased
proportion of all cases.
Sexual and household contact with another person with
hepatitis A has been among the most frequently identified
risks; in 2006, such contact was reported for 10% of cases.
During 2004–2006, the proportion of cases reported
among MSM increased from 3% to 9%, and the propor-
tion of cases in persons reporting IDU declined from 13%
to 2% (Table 4; Figure 8).
Clinical Characteristics
In 2006, the clinical characteristics of reported hepatitis
A cases were similar to previous years; 73% of infected per-
sons had jaundice, 33% were hospitalized for hepatitis A,
and 0.3% died from hepatitis A. The proportion of per-
sons hospitalized increased with age, from 22% among
children aged <5 years to 52% among persons aged >60
years (Table 5).
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Acute Hepatitis B
Overall Incidence
In 2006, a total of 4,713 acute, symptomatic cases of
hepatitis B were reported nationwide. The overall incidence
(1.6 cases per 100,000 population) was the lowest ever
recorded and represents a decline of 81% since 1990 (Tables
2 and 6; Figure 9). After asymptomatic infection and
underreporting were taken into account, an estimated
46,000 new infections occurred in 2006 (8).
Rates by Region
Hepatitis B rates continued to decline in all U.S. regions
(Figures 10 and 11). Since 2001, the highest rates have
occurred in the South.
Rates by Age
Hepatitis B rates varied by age, with the highest rate in
2006 (3.1 cases per 100,000 population) reported among
persons aged 25–44 years and the lowest (0.02 cases per
100,000 population) reported among persons aged <15
years. Rates declined in all age groups. Since 1990, the
greatest percentage declines have occurred among persons
aged <15 years (98%) and those aged 15–24 years (93%).
Although not as large as the declines in the younger age
groups, substantial decreases also have occurred among older
persons; the rates observed for persons aged 25–44 years
and >45 years have decreased 78% and 61%, respectively
(Figure 12).
Rates by Sex
As in previous years, in 2006, the rate of acute hepatitis
B for males (2.0 cases per 100,000 population) was higher
than that for females (1.1 case per 100,000 population).
Since 1990, male-to-female ratio of cases has increased
gradually. In 2006, the rate for males was approximately
1.8 times higher than that for females (Figure 13). This
difference in hepatitis B rates by sex occurred primarily
among persons aged >19 years and increased with age
(Figure 14).
Rates by Race and Ethnicity
In 2006, rates of hepatitis B continued to decline among
all racial/ethnic populations; however, recent declines have
been less than earlier in the decade (Figure 15). Rates of
hepatitis B are similar across racial/ethnic populations,
except for non-Hispanic blacks; the rate for this population
(2.3 cases per 100,000 population) was higher than for
other populations. The downward trend in the rate among
APIs continues, and, in 2006, the rate for this population
(1.2 cases per 100,000 population) was similar to Hispan-
ics and to non-Hispanic whites (1.1 case per 100,000 popu-
lation, for both populations).
Reported Risk Factors for Infection
Of persons for whom information regarding exposures
during the incubation period was available, approximately
one third reported at least one sexual risk factor (i.e., 8%,
sexual contact with a person known to have hepatitis B;
34%, multiple sexual partners; and 15%, MSM). IDU was
reported for 16% of persons. Since 2001, the proportion
of persons who reported either a sexual risk or IDU has
increased gradually as the number of cases attributable to
other sources of transmission (e.g., blood transfusions and
dialysis) has declined. The proportion of persons who
reported receiving hemodialysis or a blood transfusion (both
of which historically were major sources of infection) or
having had occupational exposure to blood was low (0.2%,
0.6%, and 0.5%, respectively) (Table 7; Figure 16).
Clinical Characteristics
In 2006, of persons reported with hepatitis B, 77% had
jaundice, 40% were hospitalized, and 0.8% died. The pro-
portion of persons hospitalized for hepatitis B increased
with age, from 12% among children aged <15 years to
51% among persons aged >60 years (Table 8).
Acute Hepatitis C
Overall Incidence
During 2005–2006, the number of confirmed cases of
acute hepatitis C reported increased 19%, from 671 to 802.
The overall national rate for 2006 was 0.3 cases per 100,000
population. After asymptomatic infection and underreporting
were taken into account, approximately 19,000 new HCV
infections occurred in 2006 (8) (Tables 2 and 9; Figure 17).
Rates by Age
Since the mid-1990s, hepatitis C rates have declined in
all age groups. However, rates appear to have reached a pla-
teau since 2003. The greatest decline has occurred among
persons aged 25–39 years, the age group that historically
has had the highest rates of disease. Among this age group,
incidence has declined 58% since 2000. In 2006, rates
increased slightly among persons aged 25–39 years (0.47
per 100,000 population) and those aged 15–24 years (0.37
per 100,000 population). Few cases are reported among
persons aged <15 years (Figure 18).
6 MMWR March 21, 2008
Rates by Sex
In 2006, as in previous years, the rate of hepatitis C was
higher for males (0.29 cases per 100,000 population) than
for females (0.25 cases per 100,000 population). However,
this differential in rates has declined over the decade. In
2006, the male-to-female ratio was the smallest since
reporting began (Figures 19 and 20).
Rates by Race and Ethnicity
Since 1995, the incidence of hepatitis C has declined in
all racial populations. In 2006, rates were similar across
racial/ethnic populations and ranged from 0.62 cases per
100,000 population among AI/ANs to 0.07 cases per
100,000 population among APIs (Figure 21).
Reported Risk Factors for Infection
Of the cases reported in 2006 for which information con-
cerning exposures during the incubation period was avail-
able, the most common risk factor identified was IDU
(54%). During the previous decade, IDU was reported for
an average of 42% of persons (range: 31%–54%). In 2006,
36% reported having had multiple sexual partners during
the incubation period, and 10% reported sexual contact
with another known HCV-infected person. Having had
surgery was reported for 16% of persons with hepatitis C.
A total of 1.5% reported occupational exposure to blood
(Table 10; Figure 22).
Clinical Characteristics
In 2006, of persons reported with hepatitis C, 66% had
jaundice, 41% were hospitalized, and 0.2% died (Table 11).
Discussion
 National surveillance data for acute viral hepatitis pro-
vides the information needed for developing prevention
strategies and monitoring their effectiveness. Since national
surveillance for acute viral hepatitis in the United States
began in 1966, major changes in the epidemiology of these
diseases have occurred. During 1995–2006, rates for all
three types of acute viral hepatitis declined dramatically.
These declines partially resulted from implementation of
comprehensive prevention strategies for each disease,
including the introduction of effective vaccines against
hepatitis A and hepatitis B.
Hepatitis A
Hepatitis A rates have varied cyclically, with peaks occur-
ring approximately every 10–15 years; the last peak in
morbidity occurred in 1995. The incidence of hepatitis A
began to decline after the introduction of licensed hepati-
tis A vaccines in the United States in 1995 and the issu-
ance in 1996 of the first public health recommendations
for the use of vaccine to prevent transmission of HAV (1).
The greatest declines have occurred since 1999, when rec-
ommendations were made for routine vaccination of chil-
dren living in states with consistently elevated rates of
hepatitis A. These recommendations called for 1) routine
vaccination of children living in states and communities
where the average hepatitis A rate during the baseline
period (1987–1997) was >20 cases per 100,000 popula-
tion (twice the national average) and for 2) consideration
of vaccination of children in those states and communities
where the average rate during the baseline period was at
least 10 cases per 100,000 but not as high as 20 cases per
100,000 population (2).
After implementation of the recommended vaccination
strategy, major changes occurred in the geographic distri-
bution of hepatitis A. Relative to their prevaccine-era rates,
a substantially greater decline occurred for the 17 western
and midwestern states that were included in the 1999 rec-
ommendation than for the remainder of the country (9).
As a result of this decline, hepatitis A rates now are similar
across all regions.
After the implementation of routine childhood vaccina-
tion, changes in the age distribution also occurred. During
the prevaccine era, the reported incidence of hepatitis A
was highest among children aged 5–14 years; approximately
one third of reported cases occurred among children aged
<15 years. Since implementation of routine childhood vac-
cination, incidence has declined more sharply among the
age groups (i.e., 2–18 years) covered by the recommenda-
tions than among older age groups. As a result, rates now
are similar among all age groups (9). In 2006, the highest
rates of disease occurred among adults, particularly among
males aged 20–44 years. The low and relatively stable rates
among persons aged >40 years reflect the higher propor-
tion of persons in this age group who had immunity as a
result of previous infection. Data from the Third National
Health and Nutrition Examination Survey (NHANES III)
conducted during 1988–1994 indicated that approxi-
mately 30% of the U.S. population had serologic evidence
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of immunity to HAV, reaching a high of 75% among per-
sons aged >70 years (10).
Disparities in rates among racial/ethnic populations also
decreased after the introduction of hepatitis A vaccine. In
particular, rates among AI/ANs were five times those of other
racial/ethnic population during the prevaccine era. Wide-
spread use of hepatitis A vaccine in Native American com-
munities began in 1996 (11), and rates in this population
now are lower than those of other racial/ethnic populations.
Hispanics also historically have had elevated hepatitis A
rates, and although incidence among Hispanics declined
>85% during 1996–2006, the 2006 rate for Hispanics
(2.3 cases per 100,000 population) is two to four times
higher than the rate for non-Hispanics.
The observed declines in the incidence of hepatitis A were
accompanied by shifts in epidemiologic profile of this dis-
ease. The substantial communitywide outbreaks that
occurred as a result of person-to-person contact in house-
holds and extended family settings have become increas-
ingly rare. The disappearance of these outbreaks can be
attributed to declining rates of infection among children
who, because they frequently have asymptomatic infection,
have often played a key role is sustaining HAV transmis-
sion. As this type of transmission has decreased, the pro-
portion of cases among persons in high-risk populations
(particularly international travelers, injection-drug users,
and MSM) has increased. Although the absolute number
of cases associated with international travel has remained
nearly unchanged, the proportion of cases attributable to
this exposure has increased, accounting for 15% of all cases
in 2006. Approximately 70% of all travel-related cases were
associated with travel to Mexico and to Central or South
America. Outbreaks of hepatitis A among injection-drug
users and MSM also have continued to occur although hepa-
titis A vaccine has been recommended for these popula-
tions since 1996.
In 2005, the licensing of hepatitis A vaccines was revised
to allow vaccination of children aged 12–23 months, which
has made feasible the incorporation of hepatitis A vaccine
into the schedule of other routinely recommended child-
hood vaccines. In 2006, ACIP recommended that all chil-
dren in the United States aged 12–23 months receive
hepatitis A vaccine (3). Nationwide hepatitis A vaccina-
tion of children is likely to result in further narrowing of
current demographic disparities and in lower overall rates
of infection. The 2006 recommendations provide the foun-
dation for eventual consideration of elimination of indig-
enous HAV transmission in the United States. Ongoing
surveillance for acute hepatitis A provides the data needed
to measure the progress toward that goal.
Hepatitis B
The decline in hepatitis B incidence began in the mid-
1980s and has coincided with the stepwise implementa-
tion of the national vaccination strategy to eliminate HBV
transmission. The 2006 rate of 1.6 cases per 100,000 popu-
lation was the lowest recorded since surveillance began in
1966 and represents an estimated decline of >80% since
the national strategy was implemented in 1991.
The greatest declines have occurred among the cohort of
children to whom the recommendations for routine infant
and adolescent vaccination have applied. During 1990–
2006, incidence among children aged <15 years declined
98%, from 1.2 cases per 100,000 population to 0.02 cases
per 100,000 population. This decline correlates with high
vaccine coverage rates among young children, with the most
recent data indicating that coverage among children aged
19–35 months is >93% (12).
Although incidence also has declined among persons aged
25–44 years, rates in this age group, particularly among
males, still remained substantially higher than in any other
age group. A high proportion of these cases occurred among
persons with risk factors for HBV infection (e.g., injection-
drug users, MSM, and persons with multiple sex partners).
The male-to-female ratio has increased gradually; in 2006,
approximately 1.8 male cases were reported for every
female case. Few cases now occur in certain populations
that previously were considered to be at high risk (e.g.,
dialysis patients and health-care workers) as a result of con-
tinued improvements in infection control and ongoing
hepatitis B vaccination in these groups. A 2003 survey
indicated that approximately 75% of health-care workers
have been vaccinated against hepatitis B (13). In 2002,
coverage among dialysis patients was 56% (14). Transmis-
sion associated with transfusions is rare as a result of
required screening of blood products. In contrast, the con-
tinued occurrence of cases among injection-drug users and
persons with sexual risk factors indicates a need to
strengthen efforts to reach these populations with vaccine.
In 2007, in collaboration with state and local health agen-
cies, CDC launched the Adult Hepatitis B Vaccination
Initiative to provide approximately $20 million of funding
for grantees to purchase hepatitis B vaccine and begin or
expand delivery of viral hepatitis prevention services in
public health settings serving adults at risk for viral hepatitis.
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Since 1990, progress has been made in reducing racial/
ethnic disparities in hepatitis B rates. Before 1990, APIs
had disproportionately higher rates of hepatitis B. The
decrease in disparity between APIs and other racial/ethnic
populations was consistent with observed declines in the
seroprevalence of HBV infection among high-risk Asian
children after the successful implementation of routine
hepatitis B vaccination (15,16). Although rates among non-
Hispanic blacks have declined, they remain more than two-
fold higher than those among other racial/ethnic
populations. Although progress has been made in reduc-
ing disparities in incidence of new infection, the impact of
these disparities in the past are reflected in current preva-
lence patterns, with higher prevalences of chronic HBV in-
fection among APIs and non-Hispanic blacks than among
other populations.
Health-care–related transmission of hepatitis B is docu-
mented infrequently in the United States but should be
considered when cases of acute viral hepatitis are identified
in persons without traditional risk factors. The declining
incidence of hepatitis B has been associated with increas-
ing recognition of sporadic cases associated with medical
care (17,18). State and local health authorities should con-
sider strategies to improve detection of health-care–
associated cases, such as targeting intensive follow-up for
persons who typically are at low risk for infection (e.g.,
persons aged >60 years).
Surveillance data for acute hepatitis B are needed for
measuring the effectiveness of the HBV-elimination strat-
egy. However, to describe completely the burden of HBV
infection in the United States and to better assess the effec-
tiveness of certain components of the prevention strategy,
other types of surveillance data also are needed. Data from
a national seroprevalence survey indicate that approximately
1.3 million persons in the United States are living with
chronic HBV infection (19). As incidence of acute hepati-
tis B continues to decline, seroprevalence surveys are needed
to validate incidence data and describe the burden of chronic
HBV infection.
Hepatitis C
After peaking in the late 1980s, the incidence of hepati-
tis C declined steadily through the 1990s. However, since
2003, hepatitis C rates have plateaued, with IDU remain-
ing the most commonly identified risk factor for infection.
Transmission of HCV associated with transfusion, an im-
portant risk for infection in previous years, was rare as a
result of required blood screening. The investigation of
persons without typical risk factors will help to ensure the
detection of transmission associated with medical care and
other uncommon sources of infection.
Since 1992, the greatest declines in incidence of acute
hepatitis C have occurred among persons aged 25–39 years,
the age group that historically had the highest rates of
infection. In 2006, cases among children continued to be
rare. Progress has been made in reducing disparities in racial/
ethnic-specific rates; in 2006, the incidence of acute hepa-
titis C was similar across all racial/ethnic populations. How-
ever, previous racial/ethnic disparities in incidence were
demonstrated by disparities in prevalence, with a higher
prevalence of chronic infection among non-Hispanic blacks
than among other racial/ethnic populations.
Although the number of new cases of acute hepatitis C
has declined, a substantial burden of disease as a result of
chronic infection still persisted in 2006. Approximately
3.2 million persons in the United States were chronically
infected with HCV; the peak prevalence occurred among
persons aged 40–49 years, the majority of whom likely
became infected in the 1970s and 1980s, when incidence
was highest (4). Data on both the incidence of acute dis-
ease and the prevalence of chronic infection are needed to
assess the burden of disease attributable to HCV infection
in the United States comprehensively. However, surveillance
for acute hepatitis C remains critical as the best means to
assess the impact of primary prevention strategies, deter-
mine where transmission continues to occur, and identify
and control outbreaks.
Limitations
The analyses summarized in this report were performed
on the basis of cases of symptomatic, serologically con-
firmed, acute viral hepatitis reported to NNDSS. NNDSS
is a passive surveillance system and subject to at least two
limitations. First, the cases reported represent only a por-
tion of all infections. Surveillance for acute disease is not
intended to identify asymptomatic infections, and certain
persons with symptomatic illness also are not identified
and reported. Studies have estimated that for each hepati-
tis case reported to NNDSS, two to five cases that would
meet the case definition are not reported (20,21). Second,
completeness of case reports also can vary. However, avail-
able evidence suggests that no systematic changes have
occurred in reporting patterns since 1990 (CDC, unpub-
lished data, 2007). The national trends in this report also
are reflected in CDC’s Sentinel Counties Study of Acute
Viral Hepatitis, in which the accuracy and completeness of
reporting were assessed and known to be high (22). Rates
based on NNDSS data represent a lower estimate of the
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incidence of acute viral hepatitis in the United States be-
cause not all cases of acute hepatitis are reported. However,
because the proportion of cases not reported has not
changed systematically over time, these estimates accurately
reflect changing trends in these diseases in the United States.
Conclusion
Surveillance for acute viral hepatitis accomplishes mul-
tiple key public health objectives. Surveillance detects out-
breaks, identifies persons in need of postexposure
prophylaxis, and provides information on trends in the
incidence and risks for recent infection that is needed to
develop and evaluate prevention strategies. The minimum
data required to conduct surveillance for acute viral hepati-
tis are laboratory confirmation of cases to distinguish the
types of acute hepatitis and clinical information to verify
the case definition. The collection of risk data provides valu-
able information for identifying modes of hepatitis trans-
mission and for implementing and evaluating prevention
strategies.
With continuing declines in the incidence of all types of
acute viral hepatitis, surveillance efforts should be enhanced
to ensure complete and accurate reporting of all cases so
that the impact of strategies for preventing or eliminating
transmission of these diseases can be monitored and evalu-
ated. In addition, effective and feasible systems for con-
ducting surveillance for chronic hepatitis virus infections
are needed to characterize the burden of chronic disease
that remains in the United States as a result of these
infections.
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TABLE 1. Percentage of acute hepatitis case reports that included hepatitis extended record data,* by state/area — United States,
2006
85%–100% 61%–84% 11%–60% 0–10%†
* Information on clinical characteristics and risk factors.
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TABLE 2. Reported number and rate* of cases of acute viral hepatitis, by type and year — United States, 1966–2006
            Hepatitis A             Hepatitis B Hepatitis C/Non-A, non-B
Year No. Rate No. Rate No. Rate
1966 32,859 16.8 1,497 0.8 —† —†
1967 38,909 19.7 2,458 1.3 —† —†
1968 45,893 23.0 4,829 2.5 —† —†
1969 48,416 24.0 5,909 3.0 —† —†
1970 56,797 27.9 8,310 4.1 —† —†
1971 59,606 28.9 9,556 4.7 —† —†
1972 54,074 26.0 9,402 4.5 —† —†
1973 50,749 24.2 8,451 4.0 —† —†
1974 40,358 19.5 10,631 5.2 —† —†
1975 35,855 16.8 13,121 6.3 —† —†
1976 33,288 15.5 14,973 7.1 —† —†
1977 31,153 14.4 16,831 7.8 —† —†
1978 29,500 13.5 15,016 6.9 —† —†
1979 30,407 13.8 15,452 7.0 —† —†
1980 29,087 12.8 19,015 8.4 —† —†
1981 25,802 11.3 21,152 9.2 —† —†
1982 23,403 10.1 22,177 9.6 2,629§ 1.1§
1983 21,532 9.2 24,318 10.4 3,470§ 1.5§
1984 22,040 9.3 26,115 11.1 3,871§ 1.6§
1985¶ 23,257 10.0 26,654 11.5 4,192§ 1.8§
1986¶ 23,430 10.0 26,107 11.2 3,634§ 1.6§
1987 25,280 10.4 25,916 10.7 2,999§ 1.2§
1988 28,507 11.6 23,177 9.4 2,619§ 1.1§
1989 35,821 14.4 23,419 9.4 2,529§ 1.0§
1990 31,441 12.6 21,102 8.5 2,553§ 1.0§
1991 24,378 9.7 18,003 7.1 3,582§ 1.4§
1992 23,112 9.1 16,126 6.3 6,010 2.4
1993 24,238 9.4 13,361 5.2 4,786 1.9
1994 26,796 10.3 12,517 4.8 4,470 1.8
1995 31,582 12.0 10,805 4.1 4,576 1.7
1996 31,032 11.7 10,637 4.0 3,716 1.4
1997 30,021 11.2 10,416 3.9 3,816 1.4
1998 23,229 8.6 10,258 3.8 3,518 1.3
1999 17,047 6.3 7,694 2.8 3,111 1.1
2000  13,397  4.8 8,036 2.9 3,197 1.1
2001 10,615 3.7 7,844 2.8 1,640** 0.7**
2002 8,795 3.1 8,064 2.8 1,223†† 0.5††
2003 7,653 2.6 7,526 2.6 891†† 0.3††
2004 5,683 1.9 6,212 2.1 758 0.3
2005 4,488 1.5 5,494 1.8 694 0.2
2006 3,579 1.2 4,713§§ 1.6§§ 802 0.3
Source: National Notifiable Diseases Surveillance System, 1996–2006.
* Rate per 100,000 population.
† Non-A, non-B hepatitis became a reportable disease in 1982.
§ Numbers and rates for hepatitis C/non-A, non-B hepatitis were unreliable, reflecting the erroneous reporting of chronically infected persons as acute
cases that occurred when testing for antibody to hepatitis C virus (anti-HCV) first became widely available.
¶ Excludes cases from New York City; data were not available for 1985–1986.
** Excludes cases from New Jersey and Missouri.
†† Excludes cases from Missouri.
§§ Excludes cases from Arizona.
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TABLE 3. Incidence* of acute hepatitis A, by state/area and year — United States, 1990–2006
State/Area 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Alabama 2.4 1.1 1.3 1.4 3.3 2.2 5.1 2.0 1.9 1.4 1.3 1.8 0.9 0.5 0.2 1.0 0.3
Alaska 34.4 16.9 22.1 129.8 34.8 8.3 8.9 5.6 2.8 2.4 2.1 2.5 1.9 1.5 0.6 0.6 0.3
Arizona 53.8 29.7 31.7 37.4 52.1 31.6 39.9 51.2 39.5 14.6 9.0 7.7 5.6 5.0 4.6 3.3 2.9
Arkansas 25.7 10.9 6.5 3.1 10.3 26.7 20.0 8.8 3.2 3.2 5.4 2.7 2.7 1.4 2.2 0.7 1.7
California 21.4 16.5 16.0 18.2 21.1 21.4 20.9 19.9 12.8 10.4 8.8 5.4 4.1 3.2 2.5 2.7 2.7
Colorado 10.7 20.2 25.5 24.6 16.0 13.6 13.4 10.3 8.7 5.4 5.2 2.0 1.6 1.4 1.1 1.0 0.9
Connecticut 4.2 3.8 2.5 3.6 3.0 2.6 4.3 4.6 3.0 3.9 5.2 7.0 2.7 2.6 2.1 1.5 1.3
Delaware 14.3 1.9 8.1 1.7 3.1 1.7 2.9 4.2 0.8 0.3 1.9 2.0 1.9 1.1 0.7 0.7 1.5
District of
Columbia 6.5 13.0 2.9 1.9 4.8 4.7 7.2 6.8 12.7 11.4 7.0 14.0 14.3 7.7 1.3 1.0 1.7
Florida 5.2 6.4 4.3 5.1 5.6 4.7 5.1 5.5 4.1 5.7 4.1 5.2 6.3 2.3 1.5 1.5 1.2
Georgia 5.8 3.7 3.4 2.1 0.6 1.2 5.6 10.2 11.5 6.2 4.6 11.1 6.0 9.1 3.6 1.4 0.6
Hawaii 9.5 7.9 14.9 5.9 4.9 14.1 10.1 12.4 4.5 2.0 1.1 1.4 2.0 1.0 2.1 1.9 0.9
Idaho 9.5 9.5 12.8 27.1 33.5 30.3 20.8 12.4 19.1 3.8 3.5 4.3 2.3 1.3 1.4 1.4 0.6
Illinois 15.1 12.2 6.7 8.7 5.2 5.6 6.4 7.2 6.8 7.0 5.6 3.5 2.1 1.5 1.2 1.0 0.8
Indiana 4.6 8.9 14.1 11.3 6.3 3.3 6.3 5.6 2.9 1.8 2.2 1.7 0.8 1.2 1.0 0.4 0.5
Iowa 10.1 1.7 1.9 2.1 2.3 3.8 11.7 17.2 14.0 5.6 2.3 1.2 2.2 1.4 1.7 0.7 0.4
Kansas 10.9 3.6 5.6 3.1 4.3 6.3 15.1 10.0 4.1 2.5 4.1 6.7 2.6 1.0 0.8 0.6 1.0
Kentucky 2.5 1.9 3.7 3.7 5.8 1.1 1.4 2.0 0.8 1.7 1.6 3.6 1.1 0.9 0.7 0.6 0.8
Louisiana 5.3 3.5 5.5 2.5 3.9 4.5 6.0 6.1 4.0 4.9 2.4 1.9 2.0 1.1 1.1 1.4 0.9
Maine 0.9 1.7 2.3 1.1 2.0 2.4 2.3 5.3 1.6 2.2 1.7 0.9 0.6 1.6 1.3 0.6 0.6
Maryland 19.8 5.6 5.2 3.2 4.0 4.4 5.1 3.7 8.1 5.9 4.0 5.5 5.5 3.2 1.9 1.5 1.1
Massachusetts 6.6 4.8 4.9 3.5 1.9 2.7 3.8 4.2 2.1 2.3 2.2 5.9 2.2 3.4 10.3 4.5 1.3
Michigan 4.1 3.1 1.6 2.2 3.7 3.8 5.2 14.0 21.7 12.7 4.9 3.3 2.2 2.0 1.4 1.0 1.2
Minnesota 7.4 10.9 19.8 11.0 5.7 4.3 3.8 5.2 3.1 2.7 3.7 0.9 1.1 1.0 1.1 0.6 0.6
Mississippi 1.8 1.3 1.6 2.3 2.9 8.3 8.3 3.5 2.5 4.6 5.0 1.3 2.2 0.6 0.8 0.7 0.3
Missouri 12.1 12.7 28.9 27.5 11.7 25.1 26.3 21.3 11.7 13.0 4.6 1.6 1.5 1.0 0.6 0.4 0.8
Montana 19.9 10.2 10.6 9.2 2.9 19.9 14.8 8.1 10.9 2.0 0.8 1.8 1.4 0.9 0.8 1.1 1.2
Nebraska 6.6 15.5 16.6 12.1 7.5 4.0 9.5 6.8 1.6 3.2 2.2 2.2 1.1 0.8 0.7 0.9 1.0
Nevada 26.3 24.2 8.3 12.6 17.4 21.9 28.1 26.1 13.0 8.1 4.5 3.3 2.5 2.3 0.7 0.9 0.4
New Hampshire 0.8 2.7 2.9 1.6 1.5 1.1 1.9 3.0 1.6 1.5 1.5 1.4 0.9 1.5 2.1 6.3 1.7
New Jersey 5.6 4.2 4.0 3.7 3.9 3.9 4.9 3.9 4.2 1.9 3.4 3.3 2.2 2.4 2.2 1.8 1.3
New Mexico 71.1 44.7 21.7 24.8 66.5 48.0 20.8 20.4 8.9 3.2 3.8 2.2 1.7 1.3 1.3 1.5 0.8
New York 11.5 10.6 6.8 6.5 8.2 8.4 5.8 7.2 5.3 3.8 4.2 4.1 3.3 3.1 2.4 2.0 1.1
North Carolina 9.7 2.4 1.6 1.4 2.1 1.5 2.8 2.8 1.7 2.2 1.9 3.0 2.5 1.5 1.2 1.0 1.2
North Dakota 5.2 10.4 22.5 12.6 0.9 3.6 21.8 2.2 0.6 0.5 0.6 0.5 0.6 0.3 0.3 0.3 0.5
Ohio 2.7 3.3 4.1 3.1 10.8 15.8 7.0 3.0 3.5 5.8 2.3 2.3 2.6 1.5 0.4 0.4 0.5
Oklahoma 19.3 9.0 6.8 6.6 12.9 43.7 78.6 43.6 20.0 15.9 7.9 3.3 1.5 0.8 0.6 0.2 0.3
Oregon 29.0 15.3 18.5 17.5 40.2 86.7 27.4 11.6 13.3 7.6 5.0 3.0 1.8 1.7 1.5 1.3 1.2
Pennsylvania 15.0 3.6 2.1 1.5 1.8 2.1 4.5 4.2 3.5 3.0 3.6 2.5 2.4 8.2 1.2 0.7 0.5
Rhode Island 5.2 11.4 17.0 7.7 3.0 3.5 2.6 13.3 1.8 3.5 3.0 7.1 3.2 1.6 2.2 1.8 1.5
South Carolina 1.3 1.2 0.6 0.5 1.1 1.2 1.5 2.9 1.4 1.2 2.4 2.1 1.6 1.3 0.9 0.9 0.6
South Dakota 70.8 119.3 30.3 2.5 5.4 13.6 5.9 3.7 5.5 1.4 0.4 0.4 0.4 —† 0.5 0.1 1.2
Tennessee 4.4 3.2 2.3 2.0 6.7 37.2 14.6 7.8 4.3 2.7 2.7 3.3 2.1 3.5 1.6 2.4 1.2
Texas 16.0 15.4 10.4 15.5 15.7 16.1 18.2 23.3 17.9 12.6 9.2 2.6 3.9 2.8 2.8 2.0 1.4
Utah 35.3 16.2 38.2 44.1 39.1 35.2 53.1 26.6 9.3 3.0 3.2 2.9 2.4 1.7 1.5 0.8 0.5
Vermont 1.1 4.2 2.5 1.6 2.4 1.4 2.0 2.5 2.9 4.0 1.6 2.6 0.6 1.0 1.3 0.8 1.3
Virginia 4.9 3.0 2.6 2.4 3.0 3.6 3.3 3.7 3.3 2.7 2.3 2.3 2.2 1.9 1.9 1.2 0.8
Washington 28.1 12.1 16.8 17.6 21.0 17.3 18.2 18.1 18.2 8.8 5.0 3.1 2.7 1.2 1.1 0.8 0.8
West Virginia 1.3 1.2 0.6 1.6 1.3 1.3 1.0 0.7 0.5 2.6 3.1 1.6 1.3 2.1 0.3 0.2 0.3
Wisconsin 9.8 15.8 18.7 10.0 4.8 3.6 3.8 3.6 3.6 1.5 2.0 1.6 3.6 0.8 2.2 0.9 0.8
Wyoming 16.1 29.5 3.0 3.6 8.6 23.0 8.5 7.3 7.7 1.9 0.8 1.4 0.6 0.4 1.0 0.2 0.4
* Per 100,000 population.
† No cases were reported.
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TABLE 4. Number and percentage* of patients with acute hepatitis A who reported selected epidemiologic characteristics,
by age group — United States, 2006
Age group (yrs)
<15 15–39 >40 Total
Characteristic* No. (%) No. (%) No. (%) No. (%)
Cases reported with risk factor data
Sexual or household contact with
hepatitis A patient 62/283 (21.9) 35/391 (9.0) 18/457 (3.9) 115/1,131 (10.2)
International travel† 66/355 (18.6) 82/470 (17.4) 48/512 (9.4) 196/1,337 (14.7)
Homosexual activity (male)§ 1/4 (25.0) 10/102 (9.8) 9/110 (8.2) 20/216 (9.3)
Injection-drug use 2/302 (0.7) 9/362 (2.5) 12/410 (2.9) 23/1,074 (2.1)
Child/employee in day care center 41/355 (11.5) 8/460 (1.7) 7/528 (1.3) 56/1,343 (4.2)
Suspected food- or waterborne outbreak 31/287 (10.8) 31/407 (7.6) 24/451 (5.3) 86/1,145 (7.5)
Contact of day care child/employee 21/326 (6.4) 19/415 (4.6) 12/463 (2.6) 52/1,204 (4.3)
Other contact with hepatitis A patient¶ 67/283 (23.7) 51/391 (13.0) 26/457 (5.7) 144/1,131 (12.7)
Unknown 175/394 (44.4) 346/550 (62.9) 506/631 (80.2) 1,027/1,575 (65.2)
Cases reported with no risk factor data
available 318 827 849 1,994
Total cases reported 712 1,377 1,480 3,569
Note: The percentage of cases for which a specific risk factor was reported was calculated on the basis of the total number of cases for which any
information for that exposure was reported. Percentages might not total 100% because multiple risk factors might have been reported for a single
case.
* Exposures that occurred during the 2–6 weeks before onset of illness.
†Of persons with hepatitis A whose cases are attributed to travel to a region endemic for hepatitis A, 72% traveled in South/Central America, 10% in
Africa, 9% in Asia/South Pacific, and 9% in the Middle East.
§Among males, 16.5% reported homosexual behavior.
¶ For example, playmate, drug-sharing contact, or care provider.
TABLE 5. Clinical characteristics of patients with acute hepatitis A, by age group — United States, 2006*
Age group (yrs)
<5 5–14 15–39 40–59 >60 Total
Characteristic No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Died from hepatitis 0/92 (0) 0/316 (0) 0/567 (0) 1/378 (0.3) 4/259 (1.5) 5/1,612 (0.3)
Hospitalized for hepatitis 21/94 (22.3) 62/319 (19.4) 188/590 (31.9) 135/389 (34.7) 143/273 (52.4) 549/1,665 (33.0)
Had jaundice 62/88 (70.5) 263/306 (85.9) 444/565 (78.6) 251/368 (68.2) 119/242 (49.2) 1,139/1,569 (72.6)
* A total of 3,579 persons with hepatitis A, including five who died, were reported. Percentages were calculated on the basis of the number of case
reports with data for age group and the outcome of interest (i.e., jaundice, hospitalization, or death).
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TABLE 6. Incidence* of acute hepatitis B, by state/area and year — United States, 1990–2006
State/Area 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Alabama 4.1 4.2 3.3 2.6 2.1 2.7 1.8 1.9 1.7 2.0 1.6 2.0 2.3 2.1 1.8 2.0 2.1
Alaska 10.5 7.2 3.6 2.5 2.2 2.2 2.6 2.5 2.1 2.9 2.1 1.6 1.9 1.2 1.7 1.2 1.2
Arizona 13.2 4.7 5.1 2.4 2.5 2.8 5.3 4.4 4.0 2.9 4.2 3.1 4.6 5.1 5.0 6.3 —†
Arkansas 5.2 6.5 4.5 3.7 2.4 3.3 3.7 4.2 4.5 3.8 4.1 4.0 4.4 3.3 4.3 2.6 3.1
California 9.8 8.6 9.2 6.0 6.5 5.5 5.4 5.1 4.4 3.7 3.2 2.5 1.8 1.9 1.4 1.1 1.2
Colorado 5.9 4.2 3.5 2.3 2.7 3.7 3.5 3.8 2.6 2.4 2.5 2.3 1.8 1.8 1.2 1.3 0.7
Connecticut 7.8 5.9 4.9 2.3 2.9 2.6 2.5 1.7 1.2 1.2 1.4 1.4 2.0 2.8 3.1 1.4 1.4
Delaware 14.6 7.9 30.3 2.6 2.0 1.3 1.2 1.0 0.5 0.1 1.9 3.6 1.7 1.7 6.4 4.4 5.5
District of
Columbia 21.4 26.5 14.6 7.5 9.4 3.8 5.9 5.7 3.6 4.8 6.1 2.3 3.9 2.3 3.4 2.4 1.5
Florida 7.4 7.2 6.9 6.2 5.4 4.7 4.6 4.4 3.5 3.9 3.8 3.1 3.3 3.7 2.9 2.7 2.3
Georgia 8.3 8.9 4.7 9.7 7.9 1.4 0.8 3.0 2.7 3.0 4.3 5.2 5.7 7.7 1.2 2.2 2.2
Hawaii 9.5 4.4 1.6 1.9 2.4 2.7 1.2 0.9 1.5 1.3 1.0 1.8 1.0 2.2 0.9 0.8 0.6
Idaho 9.1 7.0 7.9 8.1 6.8 8.8 7.4 4.5 4.0 2.3 0.8 0.8 0.5 0.6 1.0 1.0 1.0
Illinois 5.2 3.6 3.4 2.9 2.7 2.5 2.8 2.4 1.9 1.7 1.4 1.7 1.5 1.0 0.9 1.2 1.0
Indiana 6.6 4.2 4.0 4.4 3.7 4.2 2.5 1.7 2.0 1.3 1.4 1.2 1.4 1.1 1.3 0.9 1.3
Iowa 1.9 1.5 1.2 1.3 1.0 1.6 2.6 1.5 1.9 1.5 1.3 0.8 0.7 0.6 0.6 1.1 0.7
Kansas 5.6 2.4 2.6 2.6 1.2 2.0 1.2 1.2 1.1 0.6 1.0 0.5 0.9 0.7 0.7 1.2 0.4
Kentucky 12.6 5.2 2.9 2.6 2.0 1.8 2.0 1.1 1.2 1.3 2.0 1.6 1.6 2.3 2.1 1.6 1.6
Louisiana 8.9 9.1 6.1 6.3 4.7 5.6 4.8 4.8 5.0 3.9 3.5 2.8 3.0 2.6 1.5 1.5 1.5
Maine 2.4 2.6 2.2 0.9 0.9 1.0 0.6 0.5 0.4 0.2 0.4 0.5 1.1 0.5 0.9 1.1 2.0
Maryland 11.8 8.0 8.2 5.4 7.1 5.2 3.3 3.4 2.8 2.9 2.5 2.6 2.4 2.4 2.8 2.9 2.6
Massachusetts 10.7 9.1 6.4 3.6 3.3 1.9 1.8 1.3 1.3 0.7 0.2 0.6 2.6 3.3 3.1 0.8 0.3
Michigan 6.9 6.5 6.2 4.1 4.5 4.1 4.3 4.7 4.8 5.2 4.3 6.2 3.3 2.2 2.4 1.7 1.4
Minnesota 2.8 2.3 2.1 2.1 1.8 2.0 2.0 1.3 1.5 1.7 1.2 0.9 1.0 1.1 1.3 0.8 0.6
Mississippi 4.8 2.9 13.1 14.8 — — 9.0 6.6 3.4 4.7 3.9 3.3 3.2 3.9 3.5 1.8 0.4
Missouri 12.3 10.6 10.3 11.2 10.2 8.2 6.1 6.7 4.6 4.2 2.7 2.3 2.1 4.3 2.5 1.3 1.1
Montana 9.4 8.7 4.9 3.3 2.5 2.8 2.4 1.4 0.9 2.4 0.9 0.3 1.1 1.7 1.5 1.1 0.5
Nebraska 2.1 2.5 2.8 1.2 1.9 2.4 2.4 1.6 1.4 1.3 2.6 2.0 1.8 1.8 2.5 1.0 1.1
Nevada 24.3 15.0 8.0 5.4 4.1 4.3 6.0 4.8 4.6 3.3 2.7 2.5 3.3 3.9 3.3 2.0 1.7
New Hampshire 3.7 3.0 4.5 2.4 2.5 2.0 1.8 1.5 1.8 1.4 1.5 1.3 2.0 1.9 3.3 2.2 0.8
New Jersey 7.0 6.3 6.5 5.2 5.2 4.6 3.5 3.1 2.5 1.7 2.1 3.4 4.0 2.1 2.5 2.7 1.9
New Mexico 15.5 13.3 13.2 13.3 13.2 19.1 24.4 14.9 17.9 12.4 7.9 7.4 7.9 1.9 1.1 1.0 1.2
New York 7.6 5.3 5.3 4.5 5.2 5.2 4.7 4.5 3.8 2.7 3.7 4.3 4.6 1.6 1.3 1.2 1.0
North Carolina 16.4 8.3 6.3 4.5 4.1 4.3 4.6 3.6 3.2 2.9 3.2 2.7 2.8 1.9 2.1 1.9 1.8
North Dakota 1.3 0.3 0.6 0.2 0.2 0.8 0.3 1.1 0.6 0.3 0.5 0.3 1.3 0.3 0.6 0.0 0.2
Ohio 3.6 3.7 2.1 1.7 1.5 1.0 1.1 0.8 0.7 0.8 0.9 0.8 1.0 1.4 1.0 1.2 1.1
Oklahoma 5.8 6.5 5.9 6.0 4.3 5.3 1.7 2.0 5.2 5.5 5.2 3.3 3.2 2.2 2.3 1.7 2.7
Oregon 14.7 10.6 10.3 7.3 5.1 4.1 4.0 3.7 6.1 3.5 3.6 4.8 3.6 3.4 3.1 2.6 2.2
Pennsylvania 6.2 4.2 4.1 3.0 3.4 2.4 2.4 2.9 3.0 2.4 2.2 2.7 2.8 2.4 2.4 1.7 1.4
Rhode Island 5.3 2.8 2.0 1.9 0.8 1.0 1.9 2.2 7.6 4.3 4.4 3.1 3.4 2.0 0.6 0.5 1.0
South Carolina 17.8 18.7 1.5 1.4 0.9 1.5 2.7 2.6 1.7 1.6 0.6 1.8 3.3 4.8 3.5 3.1 2.2
South Dakota 1.1 1.3 0.7 — 0.6 0.3 0.7 0.1 0.5 0.1 0.3 0.1 0.4 0.5 0.1 1.0 0.6
Tennessee 17.7 19.1 21.0 22.7 20.2 12.3 9.7 8.4 5.4 3.8 4.2 4.8 2.5 3.9 3.7 2.7 2.6
Texas 10.5 11.3 8.7 7.5 7.8 6.5 6.6 6.4 9.9 4.3 5.1 3.3 5.1 4.4 3.1 3.3 3.5
Utah 6.4 2.5 1.6 3.7 5.0 3.8 6.4 4.5 3.1 1.8 1.6 1.1 2.3 2.2 2.1 1.6 1.0
Vermont 9.0 3.4 3.0 1.7 2.1 1.2 2.4 1.9 1.7 0.8 1.0 0.8 1.1 0.6 1.0 1.0 0.6
Virginia 4.5 3.5 3.0 2.4 2.2 1.8 2.4 2.0 1.6 1.5 2.4 3.0 3.1 3.1 4.1 1.9 1.0
Washington 12.6 9.4 7.7 4.7 4.8 4.2 2.9 2.1 2.4 1.9 2.2 2.9 1.4 1.5 1.0 1.0 1.2
West Virginia 4.9 3.6 3.0 2.4 2.6 2.9 2.0 0.9 0.8 1.6 1.7 1.9 1.4 2.4 2.9 3.8 4.1
Wisconsin 9.1 9.7 9.6 6.3 1.9 1.6 1.7 10.9 9.8 0.6 0.8 0.9 0.9 0.9 0.7 0.9 0.6
Wyoming 5.1 7.2 4.7 7.2 5.1 6.9 9.4 5.2 2.3 2.9 0.6 0.6 3.4 6.2 1.8 0.6 0.2
* Per 100,000 population.
† No cases were reported.
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TABLE 8. Clinical characteristics of patients with acute hepatitis B, by age group — United States, 2006*
Age group (yrs)
<15 15–39 40–59 >60 Total
Characteristic No. (%) No. (%) No. (%) No. (%) No. (%)
Died from hepatitis 0/7 (0) 2/1,357 (0.1) 13/1,108 (1.2) 8/234 (3.4) 23/2,706 (0.8)
Hospitalized  for hepatitis 1/8 (12.5) 532/1,342 (39.6) 421/1,099 (38.3) 118/233 (50.6) 1,072/2,682 (40.0)
Had jaundice 4/4 (100.0) 1,043/1,296 (80.5) 753/1,018 (74.0) 157/216 (72.7) 1,957/2,534 (77.2)
* A total of 4,713 persons with hepatitis B, including 23 who died, were reported. Percentages were calculated on the basis of the number of case
reports with data for age and the outcome of interest (i.e., jaundice, hospitalization, or death).
TABLE 7. Number and percentage of patients with acute hepatitis B who reported selected epidemiologic characteristics,
by age group — United States, 2006
Age group (yrs)
<45 >45 Total
Characteristic* No. (%) No. (%) No. (%)
Cases reported with risk factor data
Injection-drug use 276/1,304 (21.2) 50/720 (6.9) 326/2,024 (16.1)
Sexual contact with hepatitis B patient 73/886 (8.2) 35/520 (6.7) 108/1,406 (7.7)
Household contact of hepatitis B patient 11/886 (1.2) 7/520 (1.3) 18/1,406 (1.3)
Homosexual activity (male)† 81/482 (16.8) 23/231 (10.0) 104/713 (14.6)
Medical employee with blood contact 2/1,344 (0.1) 9/758 (1.2) 11/2,102 (0.5)
Hemodialysis 1/1,076 (0.1) 2/604 (0.3) 3/1,680 (0.2)
>1 sex partner 329/863 (38.1) 131/473 (27.7) 460/1,336 (34.4)
Heterosexual 294/799 (36.8) 121/455 (26.6) 415/1,254 (33.1)
Homosexual or bisexual (male) 35/64 (54.7) 10/18 (55.6) 45/82 (54.9)
Blood transfusion 5/1,316 (0.4) 8/732 (1.1) 13/2,048 (0.6)
Surgery 90/1,232 (7.3) 107/699 (15.3) 197/1,931 (10.2)
Percutaneous injury (e.g. needlestick) 47/1,149 (4.1) 37/647 (5.7) 84/1,796 (4.7)
Unknown 792/1,493 (53.0) 495/821 (60.3) 1,287/2,314 (55.6)
Cases reported with no risk factor data available 1,480 853 2,333
Total cases reported 2,973 1,674 4,647
Note: The percentage of cases for which a specific risk factor was reported was calculated on the basis of the total number of cases for which any
information for that exposure was reported. Percentages might not total 100% because multiple risk factors might have been reported for a single
patient.
* During the 6 weeks–6 months before illness onset.
†Among males, 22% reported homosexual behavior.
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TABLE 9. Incidence* of acute hepatitis C, by state/area and year — United States, 1990–2006
State/Area 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006
Alabama 0.6 0.6 0.4 0.1 0.5 0.1 0.2 0.3 0.1 0 0.2 0.1 0.2 0.1 0.1 0.3 0.2
Alaska 1.6 2.3 1.2 2.0 —† 0.5 0.5 — — — — — — — — 0 —
Arizona 2.0 0.5 0.9 0.3 0.7 1.4 1.7 0.6 0.4 1.0 0.4 0.2 0.1 0.1 0 0 —
Arkansas 0.8 0.2 0.2 0.2 0.3 0.3 0.3 0.6 1.2 1.2 0.4 0.6 0.4 0.1 0.1 0 0
California 2.1 1.3 3.4 1.8 1.8 1.6 1.5 2.7 2.6 0.6 0.3 0.3 0.2 0.1 0.1 0.1 0.1
Colorado 1.6 2.7 2.9 1.7 2.2 1.8 1.7 1.0 0.8 0.9 0.4 0.2 0.1 0.3 0.3 0.5 0.6
Connecticut 0.3 0.1 — — — — — — — — — — — — 0.1 0.3 0.4
Delaware 1.3 0.7 29.6 0.1 0.3 — 0.1 — — — 0.3 1.4 — — 5.4 0 0.4
District of
Columbia 1.3 40.8 47.6 0.5 0.4 — — — — 0.2 0.5 — — — 0.7 0 0.3
Florida 0.6 0.7 1.4 0.3 0.7 0.9 0.9 1.0 0.7 0.5 0.3 0.4 0.5 0.4 0.2 0.1 0.3
Georgia 0.2 1.5 2.0 6.5 3.1 0.4 — — 0.1 0.1 0 — 0.7 0.1 0.2 0.1 0.1
Hawaii 1.7 1.6 14.8 0.3 0.4 10.5 18.3 15.3 4.5 — 0.2 — 0.1 0.3 0.2 0.1 0.5
Idaho 0.8 0.6 — — 6.3 5.0 8.3 7.1 7.1 0.6 0.2 0.2 0.1 0.1 0.1 0.17 0.2
Illinois 0.7 0.9 1.0 0.9 0.7 0.7 0.8 0.7 0.3 0.4 0.2 0.1 0.2 0.2 0.1 0 0.1
Indiana 0.6 5.7 0.5 0.3 0.2 0.2 0.1 0.2 0.1 0.1 — 0 0 0.2 0.2 0.4 0
Iowa 0.5 0.4 0.2 0.3 0.5 0.5 1.9 1.0 0.3 — 0.1 0 0 — 0 —
Kansas 1.6 0.8 0.6 0.7 0.7 0.7 0.6 0.5 0.2 — 0.3 0.3 — — — 0 —
Kentucky 1.1 0.2 0.2 0.4 0.8 0.9 0.7 0.4 0.6 0.7 1.0 0.3 0.1 0.6 0.7 0.4 0.9
Louisiana 0.1 2.4 3.0 4.2 5 5.1 6.7 6.3 3.1 6.9 10.2 3.4 2.2 2.3 0.1 0 0.2
Maine 0.4 0.4 0.5 0.2 — — — — — 0.2 0.2 0.1 — 0.2 — 0 0.2
Maryland 0.9 1.0 0.7 0.8 0.4 0.1 0.1 0.2 0.4 0.4 0.3 0.2 0.3 0.2 0.3 0.1 0.3
Massachusetts 0.4 0.5 0.9 1.3 2.0 1.7 1.2 0.8 0.8 0.1 0.3 0.4 0.1 — 0.1 0 —
Michigan 0.5 1.5 5.1 4.2 2.1 2.5 3.6 4.0 4.8 8.3 2.0 1.4 0.9 1.0 0.8 1.0 1.0
Minnesota 0.8 0.4 0.6 0.3 0.4 0.1 0.2 0.1 0.4 0.5 0.3 0.7 0.3 0.5 0.4 0.3 0.2
Mississippi 0.6 0.4 0 0.4 — — 5.6 4.1 3.0 7.1 10.7 3.8 3.2 1.5 1.0 0.6 0.1
Missouri 0.8 0.7 0.5 0.5 0.6 0.4 0.4 0.2 0.3 5.8 10.8 19.8 10.8 4.5 0.1 0.2 0.5
Montana 0.9 4.1 3.4 0.4 1.5 2.1 2.3 2.7 0.9 0.6 0.6 0.1 0.1 0.4 0.2 0.1 —
Nebraska 0.3 0.1 5.6 0.7 0.9 1.4 0.5 0.2 0.3 0.2 0.3 0.6 0.9 0.2 0.1 0.2 —
Nevada 2.6 2.4 1.1 1.4 1.4 1.7 1.3 1.1 1.1 0.6 0.9 0.6 1.4 1.2 0.7 0.4 0.3
New Hampshire 0.8 0.8 2.2 0.7 1.0 1.2 0.6 — — — — — — — — 0 —
New Jersey 0.6 1.4 1.2 1.2 2.7 2.4 — — — — 6.7 14.3 0.1 — — 0.2 1.0
New Mexico 1.8 1.6 3.4 6.6 2.7 3.2 4.5 3.5 5.6 2.0 0.9 0.7 0.2 — 0.4 0.1 0.2
New York 0.7 1.4 1.1 1.4 1.3 1.9 1.5 1.5 0.7 0.4 0.2 0.2 0.3 0.1 0.1 0.1 0.2
North Carolina 2.2 1.7 1.3 1.2 0.8 0.9 0.6 0.7 0.3 0.4 0.2 0.3 0.3 0.2 0.1 0.2 0.2
North Dakota 0.3 0.8 0.6 0.5 0.2 1.1 — 0.6 — 0.2 0.2 — — — 0.8 0.2 —
Ohio 0.9 1.5 0.9 0.3 0.2 0.1 0.3 0.2 0.1 0 0.1 0.1 0 0.1 0.1 0.1 0.1
Oklahoma 0.9 1.5 1.5 1.5 1.9 1.7 0.2 0.3 0.7 0.5 0.5 0.2 0.6 0.2 0.2 0.4 0.5
Oregon 2.1 4.5 2.9 1.8 1.5 1.2 0.3 0.1 0.6 0.7 0.8 0.4 0.4 0.4 0.3 0.4 0.3
Pennsylvania 0.7 0.4 0.3 0.3 0.4 0.5 0.5 0.7 1.0 0.6 0.4 1.2 0.5 0.9 0.5 0.5 0.4
Rhode Island — 1.2 0.7 1.3 2.0 0.8 0.6 0.8 0.4 0.3 0.7 — 0.1 0.1 — 0 0.1
South Carolina 0.4 1.1 0 0.1 0.3 0.6 0.9 1.1 0.5 0.6 0.1 0.3 0.1 0.6 0.1 0 —
South Dakota 0.6 0.1 — — — 0.1 — — — — — — 0.1 — — 0 —
Tennessee 3.1 9.7 25.2 19.5 17.3 18.8 7.5 4.5 3.2 2.2 2.0 1.2 0.5 0.4 0.6 0.5 0.5
Texas 0.9 0.8 1.6 2.3 1.7 1.9 1.1 2.0 2.3 1.8 1.3 2.3 1.3 0.2 0.5 0.5 0.2
Utah 1.6 1.4 2.0 2.2 0.9 0.7 0.9 0.2 1.0 0.3 0.6 0.1 0.2 — 0.3 0.2 0.4
Vermont 1.4 1.2 3.0 1.0 2.8 2.4 4.4 0.7 1.0 1.2 0.8 1.1 2.4 2.1 1.3 2.7 3.7
Virginia 0.7 0.6 0.8 0.8 0.4 0.3 0.3 0.4 0.2 0.2 0 0 0.2 0.2 0.2 0.2 0.1
Washington 2.9 3.3 3.6 4.2 5.5 4.3 1.2 0.7 0.5 0.4 0.7 0.5 0.4 0.3 0.4 0.3 0.4
West Virginia 0.2 0.2 0.4 2.4 2.6 2.4 0.5 1.0 0.5 1.2 1.3 1.4 0.2 1.1 1.3 1.0 1.3
Wisconsin 0.3 2.0 2.0 0.8 — — — 0.5 2.8 0.3 — — 0.1 0.1 — 0 0
Wyoming 1.1 1.7 14.2 25.4 37.3 46.6 37.3 17.3 21.2 18.3 0.4 1.6 1.0 — 0.4 0 —
* Per 100,000 population.
† No cases were reported.
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TABLE 10. Number and percentage of patients with acute hepatitis C who reported selected epidemiologic characteristics,
By age group — United States, 2006
Age group (yrs)
<40* >40 Total
Characteristic† No. (%) No. (%) No. (%)
Cases reported with risk factor data
Injection-drug use 143/223 (64.1) 51/134 (38.1) 194/357 (54.3)
Employment in medical/dental field 1/207 (0.5) 4/128 (3.1) 5/335 (1.5)
Hemodialysis 0/198 (0) 0/119 (0) 0/317 (0)
Sexual contact with hepatitis C patient 5/58 (8.6) 4/34 (11.8) 9/92 (9.8)
Household contact of hepatitis C patient 2/58 (3.4) 0/34 (0) 2/92 (2.2)
>1 sex partner 43/126 (34.1) 29/74 (39.2) 72/200 (36.0)
Blood transfusion 0/196 (0) 0/122 (0) 0/318 (0)
Surgery 17/181 (9.4) 29/109 (26.6) 46/290 (15.9)
Percutaneous injury (e.g., needlestick) 19/179 (10.6) 8/106 (7.5) 27/285 (9.5)
Unknown 71/243 (29.2) 56/153 (36.6) 127/396 (32.1)
Cases with no reported risk factor data available 203 189 392
Total cases reported 446 342 788
Note: The percentage of cases for which a specific risk factor was reported was calculated on the basis of the total number of cases for which any
information for that exposure was reported. Percentages might not total 100% because multiple risk factors might have been reported for a single
case.
* A total of 30 (3.8%) patients were aged <19 years.
†During 6 weeks–6 months before illness onset.
TABLE 11. Clinical characteristics of patients with acute hepatitis C, by age group — United States, 2006*
Age group (yrs)
<5 5–14 15–39 40–59 >60 Total
Characteristic No. (%) No. (%) No. (%) No. (%) No. (%) No. (%)
Died from hepatitis 0/3 (0) 0/0 (0) 1/267 (0.4) 0/157 (0) 0/23 (0) 1/450 (0.2)
Hospitalized for hepatitis 2/4 (50.0) 0/0 (0) 134/297 (45.1) 63/174 (36.2) 6/24 (25.0) 205/499 (41.1)
Had jaundice 2/3 (66.7) 0/0 (0) 191/77 (69.0) 100/159 (62.9) 9/17 (52.9) 302/456 (66.2)
* A total of 802 cases of hepatitis C were reported. Percentages were calculated on the basis of the number of case reports with data for age and
outcome of interest (i.e., jaundice, hospitalization, or death).
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FIGURE 4. Incidence* of acute hepatitis A, by age group and
year — United States, 1990–2006
* Per 100,000 population.
FIGURE 3. Incidence* of acute hepatitis A, by county — United
States, 2006
Source: National Notifiable Diseases Surveillance System, 2006.
* Per 100,000 population.
FIGURE 2. Incidence* of acute hepatitis A, by region† and
year — United States, 1990–2006
* Per 100,000 population.
†Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri,
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin;
Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New
Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South:
Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia,
Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma,
South Carolina, Tennessee, Texas, Virginia, and West Virginia; and
West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana,
Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
FIGURE 1. Incidence* of acute hepatitis A, by year — United
States, 1982–2006
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FIGURE 5. Incidence* of acute hepatitis A, by sex and year —
United States, 1990–2006
* Per 100,000 population.
†The bars indicate the rate per 100,000 (the left y-axis) by sex; the line
is the ratio (right y-axis) of the incidence among males compared with
that among females.
FIGURE 6. Incidence* of acute hepatitis A, by age group and
sex — United States, 2006†
* Per 100,000 population.
†A total of 3,579 cases of hepatitis A were reported. Rates exclude
patients for whom data on age or sex were missing.
FIGURE 7. Incidence* of acute hepatitis A, by race/ethnicity
and year — United States, 1990–2006
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FIGURE 9. Incidence* of acute hepatitis B, by year — United
States, 1982–2006
* Per 100,000 population.
FIGURE 8. Trends in selected epidemiologic characteristics among patients with acute hepatitis A, by year — United States,
2000–2006*
* The percentage of cases among persons in which a specific risk factor was reported was calculated based on the total number of persons for whom
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FIGURE 10. Incidence* of acute hepatitis B, by region† and
year — United States, 1990–2006
* Per 100,000 population.
†Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri,
Nebraska, North Dakota, Ohio, South Dakota, and Wisconsin;
Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New
Jersey, New York, Pennsylvania, Rhode Island, and Vermont; South:
Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia,
Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma,
South Carolina, Tennessee, Texas, Virginia, and West Virginia; and
West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana,
Nevada, New Mexico, Oregon, Utah, Washington, and Wyoming.
FIGURE 11. Incidence* of acute hepatitis B, by county — United
States, 2006
Source: National Notifiable Diseases Surveilance System, 2006.
* Per 100,000 population.
FIGURE 12. Incidence* of acute hepatitis B, by age group and
year — United States, 1990–2006
* Per 100,000 population.
FIGURE 13. Incidence* of acute hepatitis B, by sex and year —
United States, 1990–2006
* Per 100,000 population.
†The bars indicate the rate per 100,000 (the left y-axis) by sex; the line















































































22 MMWR March 21, 2008
FIGURE 14. Incidence* of acute hepatitis B, by age group and
sex — United States, 2006†
* Per 100,000 population.
† A total of 4,713 cases of hepatitis B were reported. Rates exclude
patients for whom data on age or sex were missing.
FIGURE 15. Incidence* of acute hepatitis B, by race/ethnicity
and year — United States, 1990–2006
* Per 100,000 population.
FIGURE 16. Trends in selected epidemiologic characteristics among patients with acute hepatitis B, by year — United States,
2000–2006*
* The percentage of cases among persons for whom a specific risk factor was reported was calculated on the basis of the total number of persons
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FIGURE 17. Incidence* of acute hepatitis C, by year — United
States, 1992–2006†
* Per 100,000 population.
†Until 1995, acute hepatitis C was reported as acute hepatitis non-A,
non-B.
FIGURE 18. Incidence* of acute hepatitis C, by age group and
year — United States, 1992–2006†
* Per 100,000 population.
†Until 1995, acute hepatitis C was reported as acute hepatitis non-A,
non-B.
FIGURE 19. Incidence* of acute hepatitis C, by sex and year —
United States, 1992–2006†
* Per 100,000 population.
†Until 1995, acute hepatitis C was reported as acute hepatitis non-A,
non-B.
§The bars indicate the rate per 100,000 population (the left y-axis) by
sex; the line is the ratio (right y-axis) of the incidence among males
compared to that among females.
FIGURE 20. Incidence* of acute hepatitis C, by age group and
sex — United States, 2006
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FIGURE 22. Trends in selected epidemiologic characteristics among patients with acute hepatitis C, by year — United States,
2000–2006*
* The percentage of cases among persons for whom a specific risk factor was reported was calculated on the basis of the total number of persons
for whom any information for that exposure was available. Multiple risk factors may be reported for a single case.
FIGURE 21. Incidence* of acute hepatitis C, by race/ethnicity
and year — United States, 1992–2006†
* Per 100,000 population.
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